Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Global Blood Therapeutics, Inc. (GBT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 0.4% stake in GLOBAL BLOOD THERAPEUTICS INC |
| 10/17/2022 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 10/06/2022 |
4
| PERRY MARK L (Director) has filed a Form 4 on Global Blood Therapeutics, Inc.|
Txns:
| Disposed/sold 37,865 shares
@ $0
Disposed/sold 3,600 restricted stock units
@ $0
Disposed/sold 15,000 options to buy
@ $42.25, valued at
$633.8k
Disposed/sold 7,500 options to buy
@ $56.3, valued at
$422.3k
Disposed/sold 5,247 options to buy
@ $64.75, valued at
$339.7k
Disposed/sold 5,600 options to buy
@ $37.09, valued at
$207.7k
Disposed/sold 5,600 options to buy
@ $22.3, valued at
$124.9k
|
|
| 10/06/2022 |
4
| PATRICK DEVAL L (Director) has filed a Form 4 on Global Blood Therapeutics, Inc.|
Txns:
| Disposed/sold 9,037 shares
@ $0
Disposed/sold 3,600 restricted stock units
@ $0
Disposed/sold 625 options to buy
@ $68.75, valued at
$43k
Disposed/sold 5,247 options to buy
@ $64.75, valued at
$339.7k
Disposed/sold 5,600 options to buy
@ $37.09, valued at
$207.7k
Disposed/sold 5,600 options to buy
@ $22.3, valued at
$124.9k
|
|
| 10/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/06/2022 |
4
| YARNO WENDY L (Director) has filed a Form 4 on Global Blood Therapeutics, Inc.|
Txns:
| Disposed/sold 11,437 shares
@ $0
Disposed/sold 3,600 restricted stock units
@ $0
Disposed/sold 30,000 options to buy
@ $38.55, valued at
$1.2M
Disposed/sold 15,000 options to buy
@ $42.25, valued at
$633.8k
Disposed/sold 7,500 options to buy
@ $56.3, valued at
$422.3k
Disposed/sold 5,247 options to buy
@ $64.75, valued at
$339.7k
Disposed/sold 5,600 options to buy
@ $37.09, valued at
$207.7k
Disposed/sold 5,600 options to buy
@ $22.3, valued at
$124.9k
|
|
| 10/06/2022 |
4
| Pizzo Philip A. (Director) has filed a Form 4 on Global Blood Therapeutics, Inc.|
Txns:
| Disposed/sold 9,112 shares
@ $0
Disposed/sold 3,600 restricted stock units
@ $0
Disposed/sold 15,000 options to buy
@ $42.25, valued at
$633.8k
Disposed/sold 7,500 options to buy
@ $56.3, valued at
$422.3k
Disposed/sold 5,247 options to buy
@ $64.75, valued at
$339.7k
Disposed/sold 5,600 options to buy
@ $37.09, valued at
$207.7k
Disposed/sold 5,600 options to buy
@ $22.3, valued at
$124.9k
Disposed/sold 30,000 options to buy
@ $46.49, valued at
$1.4M
|
|
| 10/06/2022 |
4
| Svoronos Dawn (Director) has filed a Form 4 on Global Blood Therapeutics, Inc.|
Txns:
| Disposed/sold 5,376 shares
@ $0
Disposed/sold 3,600 restricted stock units
@ $0
Disposed/sold 30,000 options to buy
@ $38.68, valued at
$1.2M
Disposed/sold 7,500 options to buy
@ $56.3, valued at
$422.3k
Disposed/sold 5,247 options to buy
@ $64.75, valued at
$339.7k
Disposed/sold 5,600 options to buy
@ $37.09, valued at
$207.7k
Disposed/sold 5,600 options to buy
@ $22.3, valued at
$124.9k
|
|
| 10/06/2022 |
4
| PIERCE GLENN (Director) has filed a Form 4 on Global Blood Therapeutics, Inc.|
Txns:
| Disposed/sold 26,437 shares
@ $0
Disposed/sold 3,600 restricted stock units
@ $0
Disposed/sold 15,000 options to buy
@ $15.03, valued at
$225.5k
Disposed/sold 15,000 options to buy
@ $18.85, valued at
$282.8k
Disposed/sold 15,000 options to buy
@ $28.45, valued at
$426.8k
Disposed/sold 15,000 options to buy
@ $42.25, valued at
$633.8k
Disposed/sold 7,500 options to buy
@ $56.3, valued at
$422.3k
Disposed/sold 5,247 options to buy
@ $64.75, valued at
$339.7k
Disposed/sold 5,600 options to buy
@ $37.09, valued at
$207.7k
Disposed/sold 5,600 options to buy
@ $22.3, valued at
$124.9k
|
|
| 10/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/06/2022 |
4
| LOVE TED W (President and CEO) has filed a Form 4 on Global Blood Therapeutics, Inc.|
Txns:
| Disposed/sold 576,318 shares
@ $0
Disposed/sold 119,650 shares
@ $0
Disposed/sold 102,000 shares
@ $0
Disposed/sold 2,500 shares
@ $0
Disposed/sold 11,250 restricted stock units
@ $0
Disposed/sold 26,865 restricted stock units
@ $0
Disposed/sold 47,223 restricted stock units
@ $0
Disposed/sold 63,768 restricted stock units
@ $0
Disposed/sold 109,116 restricted stock units
@ $0
Disposed/sold 141,400 restricted stock units
@ $0
Disposed/sold 114,515 options to buy
@ $16.4, valued at
$1.9M
|
|
| 10/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/06/2022 |
4
| Farrow Jeffrey S (CFO) has filed a Form 4 on Global Blood Therapeutics, Inc.|
Txns:
| Disposed/sold 26,739 shares
@ $0
Disposed/sold 3,125 restricted stock units
@ $0
Disposed/sold 9,060 restricted stock units
@ $0
Disposed/sold 13,814 restricted stock units
@ $0
Disposed/sold 15,460 restricted stock units
@ $0
Disposed/sold 26,454 restricted stock units
@ $0
Disposed/sold 42,400 restricted stock units
@ $0
Disposed/sold 120,000 options to buy
@ $14.96, valued at
$1.8M
Disposed/sold 10,299 options to buy
@ $16.4, valued at
$168.9k
Disposed/sold 35,000 options to buy
@ $59.6, valued at
$2.1M
Disposed/sold 40,000 options to buy
@ $48.44, valued at
$1.9M
|
|
| 10/06/2022 |
4
| SUVARI TRICIA BORGA (Chief Legal Officer) has filed a Form 4 on Global Blood Therapeutics, Inc.|
Txns:
| Disposed/sold 43,077 shares
@ $0
Disposed/sold 3,125 restricted stock units
@ $0
Disposed/sold 9,060 restricted stock units
@ $0
Disposed/sold 13,814 restricted stock units
@ $0
Disposed/sold 15,460 restricted stock units
@ $0
Disposed/sold 26,454 restricted stock units
@ $0
Disposed/sold 42,400 restricted stock units
@ $0
Disposed/sold 100,000 options to buy
@ $18.25, valued at
$1.8M
Disposed/sold 40,000 options to buy
@ $59.6, valued at
$2.4M
Disposed/sold 40,000 options to buy
@ $48.44, valued at
$1.9M
Disposed/sold 38,500 options to buy
@ $65.82, valued at
$2.5M
|
|
| 10/05/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/05/2022 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 10/05/2022 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 10/05/2022 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 10/05/2022 |
8-K
| Resignation/termination of a director |
|
|
|